Viking Therapeutics Announces Participation in Key Investor Conferences This September
Viking Therapeutics to Attend Major Investor Conferences
Viking Therapeutics, Inc., the clinical-stage biopharmaceutical firm focused on developing pioneering therapies for metabolic and endocrine disorders, has officially announced its participation in several significant investor conferences scheduled for September 2026. With a line-up that includes the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum, the emphasis will be on the company's evolving portfolio designed to address obesity and related metabolic issues.
Conference Details
- - Cantor Global Healthcare Conference
Fireside Chat: September 11, from 10:20 AM to 10:50 AM ET
- - Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat: September 14, from 3:20 PM to 3:55 PM ET
A live webcast for this event will be available on the company website.
- - Bernstein 3rd Annual Healthcare Forum
Fireside Chat: September 23, from 10:30 AM to 11:10 AM ET
Viking’s management will engage in fireside chats and investor meetings to discuss its ongoing projects and future developments.
Company Overview
Viking Therapeutics is pioneering a new generation of treatments aimed primarily at metabolic disorders and obesity. Their leading candidate, VK2735, is being developed as a dual agonist for both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently undergoing Phase 3 clinical trials focused on providing effective long-term solutions for obesity, underlining the company's commitment to fostering significant health improvements for individuals struggling with weight management.
In addition to VK2735, Viking is advancing multiple therapeutic programs targeting obesity; these include VK3019, developed as an amylin receptor agonist, VK2809 designed for metabolic and liver diseases, and VK0214 aimed at treating X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder.
Viking Therapeutics emphasizes the importance of scientific rigor and deep expertise in metabolic biology, ensuring that every new treatment is rooted in meaningful research. This strategic approach aims to support patients in achieving lasting health improvements by tackling the root causes of obesity, a critical public health concern today.
Live Webcast Access
Those interested in following Viking’s developments can access the live broadcast of the fireside chat during the Morgan Stanley conference via their investor relations webpage. Additionally, a recording of the event will be available for later viewing, ensuring that stakeholders are kept informed of the latest company news and innovations.
For more details about Viking Therapeutics and their portfolio of treatments, please visit their official website at www.vikingtherapeutics.com. Their active participation in these conferences showcases their dedication to engaging with investors while highlighting their commitment to addressing critical healthcare needs through innovative therapeutic solutions.
Conclusion
In summary, Viking Therapeutics is positioning itself at the forefront of biopharmaceutical innovation, focusing on treatments for obesity and metabolic disorders. Their participation in key industry conferences not only reinforces their market presence but also facilitates valuable dialogues around vital health improvements for patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.